© Cleveland Clinic 2020
For more data like this, visit clevelandclinic.org/hvtioutcomes
HEART, VASCULAR & THORACIC
Volumes and outcomes from a sampling of centers in Cleveland Clinic’s Miller Family Heart, Vascular & Thoracic Institute
Vitals
and clevelandclinic.org/e15.
Heart Failure & Recovery
Number of heart transplants (n = 57) and LVAD implantations
(n = 101) performed in 2019
158
Number of patient referrals for advanced heart failure in 2019,
up 20% from 2018
411
(Source: Society of Thoracic Surgeons [STS] Intermacs report for 1/1/19-12/31/19)
94.6%
3-year patient survival for heart transplant recipients, vs. 84.7% national benchmark
87.0%
Our reduction in 1-year risk of graft failure vs. national benchmark
35%
Our reduction in 3-year risk of graft failure vs. national benchmark
13%
(Source: Scientific Registry of Transplant Recipients program report of 1/7/20)
1-year post-implant survival among continuous-flow LVAD recipients for destination therapy, vs. 87.0% STS Intermacs survival
91.5%
1-year post-implant survival among LVAD recipients, vs. 88.3%
STS Intermacs survival
90.8%
Electrophysiology (EP)
EP lab procedure volume, 2015-2019
28,530
EP lab procedure volume, 2019
6,290
1-year patient survival for heart transplant recipients, vs. 91.3% national benchmark
Lead extraction procedures, 2015-2019, with total of 1,705 leads extracted
897
Clinical success rate for lead extractions
97.9%
Major complication rate for lead extractions, vs. benchmark of 1.8%
1.7%
(Kusumoto et al., Heart Rhythm. 2017)
Atrial fibrillation (AF) ablations, 2015-2019
5,141
Major complication rate for AF ablations, vs. benchmark of 4.5%
1.5%
(Cappato et al., Circ Arrhythm Electrophysiol. 2010)
(Cronin et al., Heart Rhythm. 2020)
Ventricular arrhythmia ablations in patients with LVEF < 50%, 2015-2019
655
Major complication rate for these ablations, vs. benchmark of 10%
1.7%
(Boersma et al., Eur Heart J. 2016)
Placements of Watchman™ device for LAAO procedures (EP and interventional cases),
2015-2019
480
Major complication rate within 7 days of Watchman implant, vs. benchmark of 2.7%-8.7%
in published Watchman studies
1.7%
(post-March 2015 FDA approval)
LVEF = left ventricular ejection fraction; LAAO = left atrial appendage occlusion
